Connect with us


Eye Health Firm Plans Job Cuts

It will focus resources on Dextenza.




BEDFORD, MA — Ocular Therapeutix Inc., a biopharmaceutical company focused on therapies for eye conditions and diseases, announced an operational restructuring plan.

The plan is expected to result in about $11 million in annualized savings through personnel reductions and $14 million in “one-time program deferrals,” according to a press release. The company did not say how many jobs would be cut.

With the restructuring, the company is looking to focus resources on Dextenza, an FDA-approved corticosteroid indicated for the treatment of ocular inflammation and pain following ophthalmic surgery.

“We have elected to restructure Ocular in order to maximize the opportunity we have with DEXTENZA and our pipeline,” said Antony Mattessich, president and CEO. “We will use a portion of the savings generated to increase the size of our commercial field force to broaden our national reach and increase DEXTENZA promotional capabilities. Additionally, the savings are anticipated to extend our cash runway through the end of 2020 and provide an improved financial position as we build the Company for the long term.”

According to the press release:

The restructuring represents a strategic realignment and commitment by the Company to allocate capital and resources to maximize the commercial opportunity of DEXTENZA® and focus resources on progressing key pipeline assets, including completion of its DEXTENZA Phase 3 trial in allergic conjunctivitis and completion of Phase 1 trials of OTX-TIC for the treatment of glaucoma and ocular hypertension and OTX-TKI for the treatment of wet age-related macular degeneration. The Company believes the savings, combined with projected sales of DEXTENZA and cash and cash equivalents, will result in an extension of the Company’s current cash runway through the fourth quarter of 2020.




The Best Overall Progressive Lens, Now Powered by AI

Engineered with Behavioral Artificial Intelligence and utilizing new XR-motion™ technology, Varilux XR series goes beyond prescription and eye physiology to consider the patient’s visual behavior and design a progressive lens that respects how
their eyes naturally move.

Varilux XR series comes in two versions, Varilux® XR design and Varilux® XR track. The Varilux XR track lens provides an additional level of personalization by incorporating the exclusive Near Vision Behavior Measurement, providing up to 25% more near vision width3 according to the patient’s need, so patients get the highest level of customization.

Discover Varilux XR series and enjoy instantly sharp vision in motion4 and seamless transitions from near to far.

For more information, visit here.

Promoted Headlines





Get the most important news and business ideas for eyecare professionals every weekday from INVISION.



Most Popular